title: Pharmaceutical expenditure in Spain: cost and control.
abstract: In recent years, the Spanish government has been battling to keep pharmaceutical expenditures under control. Its measures include control of prices, introduction of a "negative list" of drugs no longer reimbursed, increased cost-sharing, and introduction of overall budgets for pharmaceutical expenditures. Although the average prices of old pharmaceutical products declined by 39 percent over the last 15 years and consumption in value increased by only 10 percent, real pharmaceutical expenditures in Spain increased by 264 percent over that period. The main reason for the continuing rise in these expenditures and the failure of cost-containment measures is the introduction of new, more expensive drugs, which often fail to offer any real therapeutic advantages over products already on the market. This situation is exacerbated by a lack of effective demand-side measures such as budgets for doctors and lack of a generics market.
authors: London School of Economics and Political Science, England.
authors: J
authors: J
authors: Lopez Bastida
authors: E
authors: E
authors: Mossialos
mesh_terms: D003363:Cost Control / Q000379:methods; D017047:Cost Sharing; D016527:Drug Costs / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data / Q000639:trends*; D004345:Drug Industry; D016568:Drugs, Generic; D005569:Formularies as Topic; D005102:Health Expenditures / Q000331:legislation & jurisprudence / Q000706:statistics & numerical data / Q000639:trends*; D006301:Health Services Needs and Demand; D006801:Humans; D007349:Insurance, Health, Reimbursement; D007356:Insurance, Pharmaceutical Services; D010593:Pharmaceutical Services / Q000191:economics* / Q000331:legislation & jurisprudence; D013030:Spain; D013222:State Medicine / Q000191:economics*
chemical_list: D016568:Drugs, Generic